Menu
Search
|

Menu

Close
X

BiondVax Pharmaceuticals Ltd BVXV.OQ (NASDAQ Stock Exchange Capital Market)

6.26 USD
+0.10 (+1.62%)
As of Feb 24
chart
Previous Close 6.16
Open 6.18
Volume 824
3m Avg Volume 4,138
Today’s High 6.26
Today’s Low 6.18
52 Week High 10.75
52 Week Low 4.61
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Avner Rotman
Chairman of the Board, Since 2005
Salary: --
Bonus: --
Ron Babecoff
Chief Executive Officer, President, Director, Since 2003
Salary: --
Bonus: --
Uri Ben-Or
Chief Financial Officer, Since 2007
Salary: --
Bonus: --
Tamar Ben-Yedidia
Chief Scientific Officer, Since 2004
Salary: 358,000.00₪
Bonus: --
Yisrael Gewirtz
Internal Auditor, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Weizmann Science Park
14 Einstein Street
PO Box 4143
NESS-ZIONA     7403618

Phone: +9728.9302529

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. Its technology utilizes a combination of conserved epitomes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. The Company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

SPONSORED STORIES